Optimization of Treatment and Management of Schizophrenia in Europe
- Conditions
- 10039628psychotic disorder
- Registration Number
- NL-OMON41244
- Lead Sponsor
- niversitair Medisch Centrum Utrecht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 50
•Diagnosis of schizophrenia, schizophreniform or schizoaffective disorder as defined by DSM-IV on the basis of the Mini International Neuropsychiatric Interview Plus (M.I.N.I. Plus; Sheehan et al. 1998). ;•Age 18-40 years ;•Written informed consent.
•A time interval between the onset of positive symptoms (hallucinations and/or delusions) and study entry exceeding two years.;•Prior use of antipsychotic medication longer than an episode of two weeks in the previous year and/or 6 weeks lifetime.;•Intolerance to one of the drugs in this study.;•Patients who are coercively treated at a psychiatric ward (based on a judicial ruling);•Patients who are represented by a legal ward or under legal custody;•The presence of one or more of the contraindications against any of the study drugs as mentioned in the IB texts;•Pregnancy or lactation
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method